Mark A. Velleca - 15 Sep 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: PRESIDENT & CEO, Director
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol: BDTX
Transactions as of: 15 Sep 2023
Net transactions value: +$18,749
Form type: 4
Filing time: 18 Sep 2023, 17:26:23 UTC
Previous filing: 10 Aug 2023
Next filing: 15 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDTX	Common Stock	Award	$18,749	+5,208	+13%	$3.60	46,522	15 Sep 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDTX	Stock Option (Right to Buy)	Award	$0	+1,000,000		$0.000000	1,000,000	17 Sep 2023	Common Stock	1,000,000	$3.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023.
F3	25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter.